Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rilunermin alfa - Clover Biopharmaceuticals

Next Previous
X
Search
Drug Profile

Rilunermin alfa - Clover Biopharmaceuticals

Alternative Names: Apo2L - Clover Biopharmaceuticals; Recombinant human TRAIL-Trimer fusion protein; SCB-313

Latest Information Update: 13 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Clover Biopharmaceuticals
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Apoptosis stimulants; TNF-related apoptosis-inducing ligand receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Malignant ascites
  • No development reported Malignant pleural effusion; Peritoneal cancer

Most Recent Events

  • 13 May 2024 Rilunermin alfa is still in phase-I trials for Malignant ascites in China (Intraperitoneal, Injection) (NCT04051112) (Clover Biopharmaceuticals pipeline; May 2024)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Malignant-ascites in China (Intraperitoneal, Injection)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Malignant-ascites(Second-line therapy or greater) in Australia (Intraperitoneal, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top